Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer
出版年份 2016 全文链接
标题
Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer
作者
关键词
-
出版物
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
Volume 146, Issue 4, Pages 496-502
出版商
Oxford University Press (OUP)
发表日期
2016-09-29
DOI
10.1093/ajcp/aqw134
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome
- (2016) Rhiannon K Beckers et al. HISTOPATHOLOGY
- GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas
- (2016) Drew G. Davis et al. HUMAN PATHOLOGY
- Prognostic significance of PD-L1 and PD-L2 in breast cancer
- (2016) Mauricio Z. Baptista et al. HUMAN PATHOLOGY
- The Presence of Extensive Retraction Clefts in Invasive Breast Carcinomas Correlates With Lymphatic Invasion and Nodal Metastasis and Predicts Poor Outcome
- (2015) Geza Acs et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
- (2015) H. R. Ali et al. ANNALS OF ONCOLOGY
- Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer
- (2015) G. Pruneri et al. ANNALS OF ONCOLOGY
- High Pathologic Complete Response in Her2-Positive, Early-Stage Breast Cancer to a Novel Nonanthracycline Neoadjuvant Chemotherapy
- (2015) Amelia B. Zelnak et al. Clinical Breast Cancer
- The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis
- (2015) A. Wang et al. EJSO
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy
- (2015) François Bertucci et al. Oncotarget
- Prognostic and predictive value of PDL1 expression in breast cancer
- (2015) Renaud Sabatier et al. Oncotarget
- PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics
- (2014) D. Massi et al. ANNALS OF ONCOLOGY
- Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
- (2014) Z. Gatalica et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
- (2014) Anna Sophie Berghoff et al. NEURO-ONCOLOGY
- PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
- (2014) Jason Madore et al. Pigment Cell & Melanoma Research
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Breast Cancer Subtypes and the Risk of Local and Regional Relapse
- (2010) K. David Voduc et al. JOURNAL OF CLINICAL ONCOLOGY
- Prediction of Local Recurrence, Distant Metastases, and Death After Breast-Conserving Therapy in Early-Stage Invasive Breast Cancer Using a Five-Biomarker Panel
- (2009) Ewan K.A. Millar et al. JOURNAL OF CLINICAL ONCOLOGY
- Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
- (2009) C. J. Creighton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
- (2008) X. Li et al. JNCI-Journal of the National Cancer Institute
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started